The health condition studied in "Prognostic Efficacy of Moderate Intensity rosuvastatin on the Infected cases with SARS-Cov-2" pertains to individuals diagnosed with COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. COVID-19 manifests with a spectrum of clinical presentations ranging from asymptomatic or mild respiratory symptoms to severe pneumonia, acute respiratory distress syndrome (ARDS), and multiorgan dysfunction. This study focuses on evaluating the prognostic efficacy of
Conditions
Interventions
Intervention 1: Intervention group: 10 mg of rosuvastatin in addition to the inpatient protocol treatment (hydroxychloroquine and atazanavir). Intervention 2: Control group: only the treatment of the
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: patients who were not currently taking statin treatment patients who had a confirmed diagnosis of COVID-19 based on imaging or PCR results.
Exclusion criteria
Exclusion criteria: patients with known liver disease, cirrhosis, autoimmune hepatitis, chronic viral hepatitis, rhabdomyolysis myopathy, severe kidney disease, a history of statin sensitivity, and higher-than-normal ALT and CPK in the initial test. Patients who had previously taken statins at different dosages as well as women who were pregnant or nursing If the patient developed symptoms of hepatitis or myopathy, muscle weakness and increased liver and muscle enzymes after taking statin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of disease was evaluated based on the following variables: the temperature measured by thermometer and arterial oxygen saturation measured by pulse oximeter; observation of vital signs including heart and respiratory rate on the first day of hospitalization and the day of discharge; CBC-related information including the level of CRP, ESR, WBC, Plt, ALT and CPK at the beginning of hospitalization and on the day of discharge; length of hospitalization as well as the need for ICU and intubation; shortness of breath assessed based on the Borg questionnaire and cough based on the LCQ questionnaire on the first day and at the time of discharge and after two weeks of statin administration (evaluated by phone call); and lastly, one-month mortality in cases and controls. Timepoint: on the first day and at the time of discharge and after two weeks and 1 month of statin administration. Method of measurement: thermometer, pulse oximeter, CBC, Borg questionnaire and LCQ questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamaneh Parsa
Tehran University of Medical Sciences
Outcome results
None listed